retatrutide type 2 diabetes phase 2 results 2024 ada Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Eli Lilly's retatrutide shows promising

If "exercise mimetic" is the research framing, SLU-PP-332 is the class-defining compound

Phase 3 TRIUMPH results are expected in 2026 and 2027, and Health Canada approval is likely in 2027 or 2028 if the late data holds up

But the nausea during the first month was rough I had to really watch my portion sizes and avoid fatty foods." The Downsides: The gastrointestinal side effects can be more intense than with semaglutide

CrossRef Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH Jianhua Zhang, Xujie Liu, Xian Jin, Xudong Mao, Xueli Xu, Xing Zhang, Ke Shang, Yuan Xu, Yanhuan Zhang, Guofeng Meng, Ming Yue, Guoqing Cai, Song Yang, Jinyu Huang, Jianwu Fang, Ling Pan, Lei Jiang, Stella Shi, Jianyong Shou Pharmacological Research .2025

A narrative synthesis approach was used to summarize findings across studies due to variability in study designs and outcome measures

This hormone helps regulate appetite, slow digestion, and tell your brain youre full, which can reduce how much you eat